John A. Wells

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

John A. Wells, Adam R. Glassman, Allison R. Ayala et al. · Ophthalmology · 2016 · 1K citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +12

Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy

John A. Wells, John J. Wroblewski, Jeffrey Keen et al. · Nature Genetics · 1993 · 438 citations

Medicine, Genetics, Molecular Genetics +12

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment

Neil M. Bressler, Wesley T. Beaulieu, Adam R. Glassman et al. · JAMA Ophthalmology · 2018 · 326 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +16

Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration

Gui‐Shuang Ying, Jiayan Huang, Maureen G. Maguire et al. · Ophthalmology · 2012 · 310 citations · Full text

Medicine, Ophthalmology, Vision Science +14

Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies

Huaying Fang, Qin Hui, Julie A. Lynch et al. · The American Journal of Human Genetics · 2019 · 276 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16